VWDE Inhibitors
VWDE inhibitors belong to a specialized class of chemical compounds designed to interact with the vanilloid receptor, which is a component of the transient receptor potential (TRP) family of ion channels. These inhibitors target a specific subset of these receptors known as TRPV, where V stands for vanilloid. The name VWDE (Vanilloid receptor Weak partial agonist/antagonists for Dynamic Equilibrium) reflects the unique mode of action these compounds have, which involves modulating the receptor's activity. Rather than fully blocking or activating the receptor, VWDE inhibitors delicately balance between agonism and antagonism, thus maintaining a dynamic equilibrium in the receptor's activity. This balance is critical because it allows for a subtle adjustment of the receptor's response to stimuli. The chemical structure of VWDE inhibitors is characterized by specific functional groups that enable this precise interaction with the TRPV receptors. These functional groups are arranged in such a way that they can interact with the active sites of the receptors, often involving hydrophobic and aromatic components that align with the vanilloid receptor's ligand-binding domain.
The TRPV receptors, particularly TRPV1, are known to play a significant role in the transduction of physical and chemical stimuli into cellular responses. VWDE inhibitors, due to their modulatory capacity, influence the conformation states of these ion channels. By doing so, they can affect the receptor's ability to transition between open, closed, and desensitized states. The inhibitors' weak partial agonist/antagonist activity suggests that they do not fully saturate the receptor binding sites, allowing for a reversible interaction that can be fine-tuned. The 'dynamic equilibrium' component of their action is of particular interest in the context of cellular signaling, as it suggests these compounds can influence the receptor's response to endogenous ligands and exogenous stimuli in a way that does not result in a binary on/off state but rather modulates the receptor's sensitivity and responsiveness. VWDE inhibitors, therefore, represent a unique approach to modulating the function of the TRPV receptors, providing a nuanced means of influencing these complex cellular signaling pathways without exerting overpowering effects that would come from complete agonism or antagonism.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Imatinib is a tyrosine kinase inhibitor that specifically targets BCR-ABL, c-KIT, and PDGFR. Inhibition of these kinases could downregulate several signaling pathways, potentially leading to reduced activation or expression of VWDE if it is downstream or dependent on these pathways. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor. By inhibiting the mTOR pathway, the compound could lead to a decrease in protein synthesis and cell proliferation, which may include downregulation of VWDE if it is a protein whose expression is upregulated during these cellular processes. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor. Inhibition of the PI3K/AKT/mTOR pathway can lead to reduced cell survival and proliferation. As a result, the expression or activity of VWDE could be inhibited if it is involved in this pathway. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A is a histone deacetylase inhibitor that can alter chromatin structure and gene expression. If the gene expression of VWDE is regulated by histone acetylation, this compound could potentially reduce its expression. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK1/2, which are part of the MAPK/ERK pathway. Inhibition of this pathway can alter gene expression and cellular responses to growth signals. VWDE expression or activity could be impeded if it is associated with this signaling cascade. | ||||||
WZ 4002 | 1213269-23-8 | sc-364655 sc-364655A | 10 mg 50 mg | $180.00 $744.00 | 1 | |
WZ4002 is an EGFR kinase inhibitor. By blocking EGFR signaling, it could disrupt downstream pathways that regulate cell proliferation and survival, potentially affecting the function or expression of VWDE if it is connected to EGFR signaling. | ||||||
GW4869 | 6823-69-4 | sc-218578 sc-218578A | 5 mg 25 mg | $199.00 $599.00 | 24 | |
GW4869 is an inhibitor of neutral sphingomyelinase (nSMase), affecting the ceramide pathway. Inhibition of this pathway can influence apoptosis and inflammation responses, potentially decreasing VWDE activity if it is linked to these cellular processes. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
Palbociclib is a CDK4/6 inhibitor that can arrest cell cycle progression at G1. The inhibition of cell cycle progression could lead to a reduction in the levels or activity of VWDE if it is involved in cell cycle regulation. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632 is a ROCK inhibitor that affects cytoskeleton organization and cell motility. If VWDE is involved in pathways regulating the cytoskeleton or cell migration, its activity could be indirectly reduced by this inhibitor. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor that can modulate inflammatory responses and cell differentiation. If VWDE plays a role in these processes, its activity could be indirectly diminished by the action of this inhibitor. | ||||||